←
Jing Liang 🇺🇦38,148 posts
Jing Liang 🇺🇦 avatar

Jing Liang 🇺🇦

@AppleHelix

Entrepreneur. Drug hunter. Anti-ideologues, Anti-medical nihilists, Optimist My NGO: instagram.com/sunflower.acad… sunfloweracademy.org.ua

◷ Joined December 2009▧ 3,006 Photos and videos
Jing Liang 🇺🇦 avatar
Jing Liang 🇺🇦@AppleHelix·Aug 5

I think Dr. Kurzrock is making a very important point that some people are missing. I asked Claude to create an illustration of what I mean. For a given cancer, the incidence is relatively fixed, which means the clinical trial patient pool is relatively fixed. Same pool of patients buys you 24 small ORR trials or 2 big crossover OS trials. Also, a big crossover OS RCT DOES NOT guarantee to give you a BETTER drug - which is the point @Dr_R_Kurzrock is making. Over lets say 15 years, as a PUBLIC POLICY, what regulatory approval standards will give you the GREATEST IMPROVEMENT IN CANCER CARE? This is completely DIFFERENT from the question: "which trial design will give you the most ACCURATE assessment of an individual drug's efficacy?" I also understand the argument that patients will end up paying for drugs that may not work better than SOC. Sure, this may be true at any given snapshot in time, but it is UNLIKELY TO BE TRUE over 24 iterations across 15 years. Also. I don't buy the argument that you save society money, as the # of patients treated is also relatively fixed. The same $$$ will be spent on the older SOC.

Post attachment

You didn’t need a RCT for 94% cure rate. RCT also got us Lonsurf with a 1.5% response rate, and decades of approved drugs in multiple solid tumors with median PFS or even OS of 6 to 13 months (“breakthroughs”)

FierceBiotech avatar
⟳ Jing Liang 🇺🇦 retweeted
FierceBiotech@FierceBiotech·5h

Want to land a Big Pharma deal? Be transparent, bring strong data and don't spam executives on LinkedIn. Dealmakers from GSK, Lilly, J&J, Bayer and Merck shared their advice at Fierce's London event. fiercebiotech.com/biotech/wh…

D. E. Shaw Research avatar
⟳ Jing Liang 🇺🇦 retweeted
D. E. Shaw Research@DEShawResearch·6h

We’re pleased to have collaborated with our colleagues at @NVIDIAHealth and @FlatironInst on new methods in cuPotential, helping advance the speed and accuracy of molecular dynamics simulations. We look forward to seeing how the research community puts these advances to use.

🆕 cuPotential A CUDA-X library for computing nonbonded interactions in molecular dynamics. The OpenMM plugin replaces the nonbonded force, integrator, and barostat. In NPT benchmarks on systems from 24K to 400K atoms, it ran over 3x faster than OpenMM on RTX PRO 6000 Blackwell and about 2x faster on B200, H100, A100, L40S, A10, L4, and T4. Accuracy holds up too, with a few hundred times less energy drift than default PME. 💻 Github nvda.ws/3WIwogJ 📄 Technical Blog nvda.ws/4AyIpDX 📍 Find us at #SC26 👇

Post attachment
Jing Liang 🇺🇦 avatar
Jing Liang 🇺🇦@AppleHelix·2h

On mtg/connections per step, it is 2x of JPM. On mtg/connections per elevation, 10x better

Jefferies is the new JPM. And London is a much nicer city (especially the Covant Garden area where the meetings are) than SF.

Post attachment
Archimedes avatar
⟳ Jing Liang 🇺🇦 retweeted
Archimedes@Archimedes20311·4h

Bodes well for many cos thinking about orphan products. N=36 vs external control $CAMP $SPRB $RARE $JSPR $QURE

Today, we have approved the first treatment shown to help people with an infantile onset form of Niemann-Pick disease type C (NPC) live longer. Approved for adults and children weighing ≥7 kg (about 15 pounds) whose neurological symptoms began before age 6, the approval of this new treatment marks an important milestone for the rare disease community. fda.gov/news-events/press-an…

Post attachment
Rich Law avatar
⟳ Jing Liang 🇺🇦 retweeted
Rich Law@drrichjlaw·13h

Jefferies is the new JPM. And London is a much nicer city (especially the Covant Garden area where the meetings are) than SF.

Post attachment
Jing Liang 🇺🇦 avatar
Jing Liang 🇺🇦@AppleHelix·Nov 17

This guy is the current Spanish minister of social affairs.

Nadie en España va a heredar más de lo que pueda gastarse en una vida. A partir de 10 millones de euros, el dinero va a ir a los servicios públicos, que son el patrimonio de todos los demás. ¿Qué mérito hay en nacer en una familia rica? ¿Qué apellido vale 10 millones de euros?

0:56
Adam Feuerstein ✡️ avatar
⟳ Jing Liang 🇺🇦 retweeted
Adam Feuerstein ✡️@adamfeuerstein·Nov 16

FDA approves new breast cancer drug, providing new option for some patients, boost for Roche statnews.com/2026/11/16/fda-… via @DrewQJoseph

Jing Liang 🇺🇦 avatar
Jing Liang 🇺🇦@AppleHelix·Nov 16

A Big Pharma BD group is looking for PhDs (life sciences) with prior BD experience (not too senior). Needs to be based in SF area. DM me if you fit the profile.

Jing Liang 🇺🇦 avatar
Jing Liang 🇺🇦@AppleHelix·Nov 16

These deals are also why big VCs will keep playing the clinical stage spinout game. Back a CMO, in-license clinical stage eye assets. Amazing IRR and absolute returns.

NEW from @FT: Johnson & Johnson is poised to buy privately held eye disease drug developer Ollin Biosciences for up to $3.4bn, the latest in a glut of bolt-on acquisitions in the biotechnology sector.

Post attachment
Raffaele Colombo avatar
⟳ Jing Liang 🇺🇦 retweeted
Raffaele Colombo@raffcolo·Nov 15

TROPION-Breast01: dual primary endpoints of PFS and OS. PFS was positive and OS was not statistically significant (HR 1.01), FDA approved it. HARMONi: also dual endpoints, PFS met, OS not met, FDA sent a CRL. 🤔🤔🤔

🟡 Whoa, Sunday CRL for ivonescimab! “The FDA indicated that PFS benefit in the absence of a statistically significant OS benefit does not support a positive benefit-risk profile in support of approval.”

Post attachment
Veli Bakalov, MD avatar
⟳ Jing Liang 🇺🇦 retweeted
Veli Bakalov, MD@HemeOncBuddy·Nov 15

I am so confused! 🤷🏼‍♂️🤨 please help me! June 2025: FDA gives Dato-DXd accelerated approval in EGFR mutated mNSCLC after TKI. Decision was made on a pooled 45% ORR from single-arm phase 2 and a subgroup of a phase 3. Yes decision was made based on polled ORR from two different trials enrolling patients under DIFFERENT inclusion/exclusion criteria! 🤯 Nov 2026: randomized phase 3 trial meeting its primary end point - PFS. FDA says PFS without significant OS is not enough. And I agree! But pooled single-arm response rates were enough for Dato-DXd. Same disease. Double standard.🙅🏼‍♂️ FDA gave accelerated approval to Dato-DXd with a confirmatory trial pending. And that trial is TROPION-LUNG15 with primary end point being PFS!!!😵 so if no OS benefit FDA should withdraw approval right? In fact, let’s go back and remove all drugs that don't have OS benefit! For Datao-dxd the label covers patients after an EGFR TKI and platinum chemo. Lung15 compares Dato-DXd against platinum doublet in patients with EGFR NSCLC and disease progression on prior osimertinib. So the trial would confirm benefit one line earlier than the approval is! 🤦🏼‍♂️ PS IMO neither of the drugs should be approved 😁